[go: up one dir, main page]

HK1223832A1 - 用於癌症治療的激酶抑制劑 - Google Patents

用於癌症治療的激酶抑制劑

Info

Publication number
HK1223832A1
HK1223832A1 HK16112097.9A HK16112097A HK1223832A1 HK 1223832 A1 HK1223832 A1 HK 1223832A1 HK 16112097 A HK16112097 A HK 16112097A HK 1223832 A1 HK1223832 A1 HK 1223832A1
Authority
HK
Hong Kong
Prior art keywords
cancer
treatment
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
HK16112097.9A
Other languages
English (en)
Inventor
David Lawson Morris
Original Assignee
Pitney Pharmaceuticals Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2012901199A external-priority patent/AU2012901199A0/en
Application filed by Pitney Pharmaceuticals Pty Ltd filed Critical Pitney Pharmaceuticals Pty Ltd
Publication of HK1223832A1 publication Critical patent/HK1223832A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/24—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton
    • C07C255/29—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the same saturated acyclic carbon skeleton containing cyano groups and acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16112097.9A 2012-03-23 2015-06-19 用於癌症治療的激酶抑制劑 HK1223832A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2012901199A AU2012901199A0 (en) 2012-03-23 Kinase inhibitors for the Treatment of Cancer

Publications (1)

Publication Number Publication Date
HK1223832A1 true HK1223832A1 (zh) 2017-08-11

Family

ID=49221707

Family Applications (2)

Application Number Title Priority Date Filing Date
HK16112097.9A HK1223832A1 (zh) 2012-03-23 2015-06-19 用於癌症治療的激酶抑制劑
HK15105896.7A HK1205500A1 (zh) 2012-03-23 2015-06-19 用於癌症治療的激酶抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15105896.7A HK1205500A1 (zh) 2012-03-23 2015-06-19 用於癌症治療的激酶抑制劑

Country Status (12)

Country Link
US (2) US9308193B2 (zh)
EP (2) EP2817286B1 (zh)
JP (2) JP6165231B2 (zh)
KR (1) KR102055176B1 (zh)
CN (2) CN105534969B (zh)
AU (2) AU2013234869B2 (zh)
CA (1) CA2868120C (zh)
ES (2) ES2732229T3 (zh)
HK (2) HK1223832A1 (zh)
NZ (2) NZ630807A (zh)
PL (1) PL2817286T3 (zh)
WO (1) WO2013138863A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3202397B1 (en) * 2012-08-06 2019-09-25 Pitney Pharmaceuticals Pty Limited Compounds for the treatment of mtor pathway related diseases
CN105792823B (zh) 2013-11-01 2019-11-12 皮特尼制药股份有限公司 治疗恶性肿瘤的药物组合
EP3261636A1 (en) * 2015-02-24 2018-01-03 Pitney Pharmaceuticals Pty Limited Anti cancer agent comprising aminoacetonitrile compound as active ingredient
WO2021177334A1 (ja) * 2020-03-04 2021-09-10 国立大学法人山口大学 新規なフルオロアルカン誘導体及びそれらを用いたゲル化剤
CA3183094A1 (en) * 2020-05-11 2021-11-18 Pitney Pharmaceuticals Pty Limited Use of aminoacetonitrile compounds for the treatment of infection and disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584305A (en) * 1972-08-17 1986-04-22 Janssen Pharmaceutica N.V. Aiding the regression of neoplastic disease with 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AT408615B (de) 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
AR036054A1 (es) * 2001-06-15 2004-08-04 Novartis Ag Uso de compuestos de aminoacetonitrilo para el control de plagas, una composicion y un proceso para dicho control y una composicion farmaceutica contra parasitos
GB0402677D0 (en) * 2003-11-06 2004-03-10 Novartis Ag Organic compounds
AR049391A1 (es) * 2004-06-10 2006-07-26 Novartis Ag Derivados de aminoacetonitrilo y su uso para controlar parasitos en animales de sangre caliente
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
CN102127074A (zh) * 2010-12-17 2011-07-20 中国药科大学 6-氨磺酰基取代-β-咔啉-1-酮类细胞周期蛋白依赖性激酶2抑制剂及其用途

Also Published As

Publication number Publication date
JP6483736B2 (ja) 2019-03-13
EP3061451B1 (en) 2019-05-08
NZ714625A (en) 2017-02-24
JP6165231B2 (ja) 2017-07-19
AU2016204389A1 (en) 2016-07-14
KR20140145604A (ko) 2014-12-23
EP3061451A1 (en) 2016-08-31
US20150051290A1 (en) 2015-02-19
WO2013138863A1 (en) 2013-09-26
HK1205500A1 (zh) 2015-12-18
AU2013234869B2 (en) 2016-06-30
US9308193B2 (en) 2016-04-12
CN105534969A (zh) 2016-05-04
CN104364232B (zh) 2017-05-31
EP2817286A1 (en) 2014-12-31
EP2817286B1 (en) 2018-06-06
US20160220527A1 (en) 2016-08-04
CA2868120A1 (en) 2013-09-26
ES2732229T3 (es) 2019-11-21
JP2015510898A (ja) 2015-04-13
KR102055176B1 (ko) 2019-12-12
CN105534969B (zh) 2019-04-05
JP2017125041A (ja) 2017-07-20
EP2817286A4 (en) 2015-09-02
NZ630807A (en) 2016-04-29
CN104364232A (zh) 2015-02-18
PL2817286T3 (pl) 2018-11-30
CA2868120C (en) 2019-02-19
ES2685612T3 (es) 2018-10-10
AU2013234869A1 (en) 2014-10-02
AU2016204389B2 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
IL274318A (en) Cancer treatment with rapamycin target site kinase inhibitors
HK1243919A1 (zh) 利用tor激酶抑制劑治療癌症
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HK1207861A1 (zh) 作為 抑制劑的用於治療癌症的取代的環烯並吡唑
PT3418281T (pt) Pirazolo[1,5-a]pirimidinas úteis como inibidores da quinase atr para o tratamento de doenças de cancro
HK1210174A1 (zh) 用於治療過度增殖性|疾病的絲氨酸/蘇氨酸激酶抑制劑
EP3019491A4 (en) KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
HK1202247A1 (zh) 激酶抑制劑治療癌症
HK1201750A1 (zh) 使用 激酶抑制劑的癌症治療
HK1206338A1 (zh) 用於治療癌症的嘧啶化合物
HK1201753A1 (zh) 使用 激酶抑制劑的癌症治療
HK1223832A1 (zh) 用於癌症治療的激酶抑制劑
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
AU2012901199A0 (en) Kinase inhibitors for the Treatment of Cancer
ZA201502294B (en) Treatment of cancer with tor kinase inhibitors
HK1200094A1 (zh) 免疫調節劑用於治療癌症的用途